LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.99 USD -9.17% Market Closed
Market Cap: 26m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LAVA Therapeutics NV
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Interest Income Expense
$1.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Interest Income Expense
-$2.9m
CAGR 3-Years
52%
CAGR 5-Years
37%
CAGR 10-Years
9%
ProQR Therapeutics NV
NASDAQ:PRQR
Interest Income Expense
€2.5m
CAGR 3-Years
N/A
CAGR 5-Years
7%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Interest Income Expense
-$34.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-36%
argenx SE
XBRU:ARGX
Interest Income Expense
$115m
CAGR 3-Years
N/A
CAGR 5-Years
24%
CAGR 10-Years
104%
Merus NV
NASDAQ:MRUS
Interest Income Expense
-$6.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
26m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.18 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Interest Income Expense?
Interest Income Expense
1.6m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Interest Income Expense amounts to 1.6m USD.

What is LAVA Therapeutics NV's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
-51%

Over the last year, the Interest Income Expense growth was -51%.

Back to Top